Neuritic extension is the resultant of two vectorial processes: outgrowth and retraction.
INTRODUCTION
Neuronal growth cone motility is intrinsic to the formation of the mammalian central and peripheral nervous systems during development (Letourneau et al., 1991; Gordon-Weeks, 2000) . Growth cone advance occurs through adhesive interactions with the surrounding extracellular matrix in response to external guidance cues; such movement is the result of two alternating processes, outgrowth and retraction, necessary in order to achieve net protrusive advance (Kater and Guthrie, 1990; Letourneau et al., 1991; Gordon-Weeks, 2000) .
Elaboration and subsequent disassembly of focal contacts at the leading edge of the growth cone in response to Rac-and Rho-dependent signalling pathways (Hall, 1998; Luo, 2000) , brings about changes in trajectory. Such regulatory cascades target the activity of molecular motors and the arrangement of the actin cytoskeleton, which determine growth cone directionality.
The neuronal growth cone comprises two very distinct regions (Bridgman and Dailey, 1989; Lewis and Bridgman, 1992) : a relatively massive central domain (C), containing the bulk of the actin cytoskeleton in which actin is arranged as a three-dimensional meshwork, and a thin peripheral region (P), encompassing the lamellipodium and filopodia. Actin within the P domain originates at the leading edge and is propelled backwards by retrograde actin flow (Lin and Forscher, 1995) . Lamellipodial protrusion, as distinct from neuritic process outgrowth, is a dynamic activity localised entirely within the P domain; it is driven by dendritic nucleation under the control of Arp 2/3 and does not necessarily require myosin action (Pantolini et al., 1999; Borisy and Svitkina, 2000) , although myosin participation is not excluded (Wang et al., 1996; Diefenbach et al., 2002) . However, much greater forces are required to achieve neuritic process dynamics and these forces operate within the C domain and at its periphery with the P domain to move the bulk of the growth cone cytoskeleton.
Actin microfilaments constitute the bulk of the cytoskeleton in this region (Chang and Goldman, 1973; Letourneau, 1981; Lewis and Bridgman, 1992) and consequently actin-based motors are likely to be responsible for fundamental aspects of growth cone movement.
The myosin superfamily comprises at least 18 separate classes of molecule (Berg et al., 2001) . Members of the "conventional" class II myosins (Kuczmarski and Rosenbaum, 1978; Cheng et al., 1992; Miller et al., 1992; Li et al., 1994; Rochlin et al., 1995; Ruchhoeft and Harris, 1997) as well as isoforms of "uncoventional" myosins of classes I Miller et al., 1992; Wagner et al., 1992; Lewis and Bridgman, 1996; Wang et al., Page 4 of 28 1996), V (Espreafico et al., 1992; Wang et al., 1996; Coling et al., 1997) , VI (Suter et al., 2000) and X (Berg and Cheney, 2002) , have been found in neuronal growth cones. It would appear likely that these different isoforms perform distinct tasks during the normal functioning of the cell. However, while myosin V (Wang et al., 1996) and myosin 1c (Diefenbach et al., 2002) have been implicated in lamellipodial dynamics, and myosin X in intrafilopodial motility, it would appear that the forces responsible for neurite extension are generated by conventional myosin isoforms (Wylie et al., 1998; Bridgman et al., 2000; Wylie and Chantler, 2001) .
At least two different isoforms of conventional myosin, expressed from separate genes (A and B), are found in neuronal cells (Katsuragawa et al., 1989; Kawamoto and Adelstein, 1991; Simons et al., 1991) , myosin IIB being the predominate isoform (Katsuragawa et al., 1989; Kawamoto and Adelstein, 1991; Miller et al., 1992; Itoh and Adelstein, 1995; Rochlin et al., 1995) . These isoforms exhibit differential localisation within the growth cone; myosin IIB, found in the P domain and adjacent to the C-domain, exhibits a more peripheral distribution than myosin IIA, which is located mainly within the C-domain and does not extend into the marginal zone (Rochlin et al., 1995) . Isoform sorting of these conventional myosins may occur by mechanisms intrinsic to their structures (Kolega, 1998) . Using antisense knockdown and transgenic knock-out approaches, respectively, we (Wylie et al., 1998) and others (Bridgman et al., 2001 ) have identified myosin IIB as the molecular motor responsible for neurite outgrowth. We have also shown that myosin IIA, while not directly involved in outgrowth per se, is required for assembly of focal contacts which provide adhesion (Wylie and Chantler, 2001) , against which the forward propulsive force acts (Lamoureux et al., 1989) . If myosin IIB drives outgrowth and myosin IIA is responsible for tension maintenance during adhesion, it remains to determine what kind of motor is responsible for driving neurite retraction. Here, using an isoform-specific functional knock-down approach combined with pharmacological targeting, we show that myosin IIA, but not myosin IIB, drives neurite retraction.
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METHODS and METHODS

Cell culture and cytochemistry
Neuro-2A cells were cultured as described previously (Wylie et al., 1998; Wylie and Chantler, 2001) . Cytochemistry was preceded by a brief extraction step (Cramer and Mitchison, 1995) in cytoskeletal buffer (10 mM MES pH 6.1, 138 mM KCl, 3 mM MgCl 2 , 2 mM EGTA) supplemented with 0.32 M sucrose, 0.1% Triton-X100 and 1 µg/mL phalloidin, followed by fixation for 30 minutes in cytoskeletal buffer supplemented with 0.32 M sucrose and 4% formaldehyde, as described (Wylie and Chantler, 2001 ). Cells were permeabilised for 10 minutes in PBS plus 0.5% Triton-X100, rinsed in PBS then immersed in a blocking solution comprising 2% de-complemented horse serum in PBS for 20 minutes. Incubation with primary and secondary antibodies was performed as described previously (Wylie and Chantler, 2001 ). Nonmuscle myosin IIA was detected by indirect immunofluorescence using polyclonal rabbit anti-nonmuscle (rat) myosin IIA as primary antibody (Choi et al., 1996) (1:300 dilution) and Alexa-Fluor 633-conjugated goat anti-rabbit IgG (Molecular Probes)(1:100 dilution) as secondary antibody. Paxillin was detected by direct immunofluorescence using a FITC-conjugated monoclonal mouse antipaxillin IgG (BD Biosciences)(1:100 dilution) (Leventhal and Feldman, 1996) . Filamentous actin was detected using Texas Red phalloidin (Molecular Probes) added at a concentration of 165 nM. All antibody dilutions were made up in 1% de-complemented horse serum/PBS including 0.1% Triton-X100/1.5mM sodium azide. Coverslips were mounted using MOWIOL (Calbiochem)/glycerol (25% v/v)/50mM Tris pH 8.5/DABCO (2.5% w/v)/3mM sodium azide.
Antisense treatment protocols
Sequences of the isoform-specific antisense and sense oligonucleotides used in these studies, together with the scrambled (control) oligonucleotides used, are displayed in Table I . For myosin IIA, sense oligonucleotides (AQ5) were synthesized to correspond to a region of isoform-specific sequence located towards the 5' end of the transcript, where it normally codes for the amino acid sequence NPILEA (Accession number U31463 (Choi et al., 1996) ). The antisense oligonucleotide sequence (AQ3) was the inverse complement of AQ5. For myosin IIB, sense oligonucleotides (BQ5) were synthesized to correspond to a region of isoform-specific sequence within the 5' coding region of the myosin IIB transcript which codes for the amino acid sequence ADPILES (Accession number U15766 (Itoh and Adelstein, 1995) ). The antisense oligonucleotide sequence (BQ3) was the inverse complement of BQ5. Scrambled (control) oligonucleotides corresponded in base Page 6 of 28 composition to those of the antisense oligonucleotides except that the sequence was scrambled and did not match any other entry in the Genbank or EMBL databases.
Neuro-2A cells in culture were transferred to serum-free media and treated separately, or in combination, with sense, antisense or scrambled oligonucleotides derived from myosin IIA or myosin IIB sequences. Initial incubations took place with 50µM oligonucleotides while subsequent additions, every 12 hours, were at 25µM (Wylie et al., 1998) . At appropriate times, cells were fixed then examined by DIC microscopy, or stained with antibodies prior to viewing by confocal laser scanning microscopy. Where performed, RT-PCR was carried out as described previously (Wylie et al., 1998; Wylie and Chantler, 2001 ).
Confocal laser scanning and DIC microscopy
Confocal fluorescence microscopy was performed, as described previously (Wylie and Chantler, 2001) , using a Zeiss LSM 510 confocal laser scanning microscope equipped with a 40x Fluar oil immersion objective (N.A.
1.3), argon (λ ex = 488 nm) and He-Ne (λ ex = 543 nm) lasers. Neurite outgrowth was monitored through differential interference contrast (DIC) microscopy using a Zeiss Axiovert 135 inverted microscope. Images were digitized prior to neurite length measurement using Kontron 300 software. Statistical analysis was performed as described (Wylie et al., 1998; Wylie and Chantler, 2001 ).
Application of LPA, Thrombin and Y27632. Serial measures on individual neurites.
LPA (1µM, Sigma) and thrombin (5 NIH units (75µg) per ml, Sigma) were freshly prepared in media from appropriately diluted stock solutions and added as a 20µL pulse to the cultured cells, in a pre-selected quadrant of the coverslip under observation (Jalink and Moolenaar, 1992; Suidan et al., 1992) , initiating retraction. In those experiments where the Rho-kinase inhibitor Y27632 (50µM, Calbiochem) was required, it was added 30 minutes prior to the addition of either LPA or thrombin.
For serial measures, the same patch of cells was monitored using DIC optics from the start of the timed series, digitised images (Kontron KS-300) being stored at the following intervals: 0, (Wylie et al., 1998) . Here, we have applied a 96-hour myosin IIB oligonucleotide treatment window to cells that had already been allowed to extend processes for various times up till 120 hours.
An underlying retractive process was uncovered upon application of the myosin IIB antisense treatment window (Figure 1 ) whereas sense, scrambled or untreated controls had no effect. To examine whether lysophosphatidic acid (LPA) was able to induce neurite retraction in
Neuro-2A cells, as has been observed in other cells of neuronal origin (Tigyi and Miledi, 1992; Jalink et al., 1993) , Neuro-2A cells were grown in culture for 72 hours before addition of LPA (1µM). This pulse of LPA induced rapid process retraction that was virtually complete within 30 minutes ( Figure 4a ). This effect could be blocked entirely by prior addition of the Rho-kinase inhibitor, Y27632 (25µM), 30 minutes before LPA application We also determined that thrombin could induce neurite retraction in Neuro-2A cells, as has been observed in other cells of neuronal origin (Jalink and Moolenaar, 1992; Suidan et al., 1992) . Thrombin (pulse optimised at a concentration of 5.0 NIH units/mL, as determined from a dose/response curve) caused immediate retraction of pre-formed neurites ( Figure 5a ).
This could be blocked completely by Y27632 (25 µM 
Y27632 does not inhibit neurite outgrowth.
Having used Y27632 to inhibit neurite retraction (Figures 4 & 5) , we also examined whether or not this Rho kinase inhibitor had any effect on neurite outgrowth. Application of Y27632
to Neuro-2A cells at various times after plating demonstrated no inhibition of neurite outgrowth ( Figure 6a) . Indeed, the rate of outgrowth was somewhat enhanced. In a separate series of experiments Y27632 was applied continuously from the time of plating then antisense oligonucleotides directed against myosin IIB were added at later times ( Figure 6b ).
Under these conditions, myosin IIB antisense oligonucleotides remained effective at halting outgrowth, irrespective of the time of application. These results further suggest that Y27632
and myosin IIB antisense oligonucleotides interfere with separate pathways, and thereby
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imply that retraction and outgrowth, respectively, involve distinctive molecular motors regulated by separate pathways.
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DISCUSSION
The ability of neuronal cells to project long processes, with lengths up to several thousand times the diameter of a cell body, has engaged the interests of cell biologists since the first observations by Ramón y Cajal at the end of the nineteenth century. Growth cones located at the tips of neuritic processes control the extension of these protrusions in vivo, which lengthen in response to a variety of external cues, integrating activity-dependent growth with attractive or inhibitory signals that arise from the extracellular matrix and synaptic targets (Kater and Guthrie, 1990; Letourneau et al., 1991; Gordon-Weeks, 2000; Luo, 2002) . Net growth evolves from a balance of forces, the mechanism involving alternation between periods of outgrowth and retraction, attachment and detachment. Each of these operational modes is presumably determined by the actions of one or more molecular motors, the activities of which must be co-ordinated in order to generate a resultant displacement in the required direction. We have shown previously that the molecular motors, myosin IIB and myosin IIA undertake different roles in this process: myosin IIB drives outgrowth (Wylie et al., 1998) whereas myosin IIA maintains tensile adhesion (Wylie and Chantler, 2001 ). Here, we show that myosin IIA also drives neurite retraction.
By introducing isoform-specific myosin IIB oligonucleotides at different times after initiation of neurite outgrowth rather than continuously from the time of plating, as described previously (Wylie et al., 1998) , we were able to observe an underlying process of continual neurite retraction (Figure 1 ). This retraction is, in turn, inhibited by antisense nucleotides directed against myosin IIA, which is thus the agent of the retraction process. Most striking, our observations are consistent with a constitutive retraction process that requires myosin IIA but is independent of myosin IIB. It is of interest to note that retraction is never complete, but ceases at neurite lengths approximately 10-20 µm from the cell body (Figure 1 ). This limit may represent a differentiative boundary below which committed neurites can no longer shorten, an interpretation consistent with different roles for upstream regulators during neurite initiation as compared with neurite elongation (Sebok et al., 1999) .
Initial outgrowth up to ~20 µm occurs in the presence of myosin IIB antisense oligonucleotides (Wylie et al., 1998) (Figure 2, c & d) . Thus, the dynamics of neurite extension (Wylie et al., 1998; Bridgman et al., 2001; Wylie and Chantler, 2001 ) and lamellipodial protrusion (Rochlin et al., 1995; Wang et al., 1996; Diefenbach et al., 2002) are, by implication, controlled by separate mechanisms.
To exclude the possibility that myosin IIA antisense effects arise from disruption of the actin cytoskeleton, we used LPA or thrombin to induce rapid neurite retraction in Neuro-2A cells that had been incubated with oligonucleotides for too brief a time to cause cytoskeletal disruption (Figures 3-5) . Observation of the actin cytoskeleton by confocal microscopy did not identify any disturbance of the cytoarchitecture as a consequence of the relatively brief (48 hours) incubation with myosin IIA antisense oligonucleotides (Figure 3 ). LPA and thrombin bind to different cognate heterotrimeric Ras family G-protein-coupled receptors; in either case binding engenders Rho activation, growth cone collapse and neurite retraction (Jalink et al., 1994; Tigyi et al., 1996; Katoh et al., 1998b) . LPA-induced retraction of neurites from N1E-115 cells has been shown to be inhibited by Y-27632 (Hirose et al., 1998) , itself a specific inhibitor of Rho-kinase (also known as p160ROCK or ROKα). Rho-kinase is also known to induce neurite retraction (Hirose et al., 1998; Katoh et al., 1998a) and its action involves myosin II activation (Amano et al., 1998) . Rho kinase, activated by Rho, phosphorylates and thus inhibits myosin light chain phosphatase, leading to the persistence of myosin II-actin interaction. Y27632 inhibits the action of Rho-kinase; phosphatase activity is consequently preserved and the myosin regulatory light-chain is dephosphorylated, thereby terminating cross-bridge cycling.
Our data show that both LPA-and thrombin-induced Neuro-2A cell neurite retraction, which reaches completion within 30 minutes of addition of agonist, can be inhibited by prior exposure to antisense oligonuclotides directed against myosin IIA transcripts (Figures 4 & 5) .
Inhibition is essentially complete (Figures 4d & 5d) , as also seen when Y27632 alone is added (Figures 4b & 5b) . Most importantly, antisense-dependent inhibition is isoform-specific:
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Two possible interpretations arise to explain why myosin IIB antisense oligonucleotides have a small effect (Figures 4f & 5f ), rather than none at all. Either myosin IIB could act, in part, as a retraction motor or, alternatively, the action of myosin IIA requires normal myosin IIB functionality. The observation that myosin IIA antisense oligonucleotides alone inhibit retraction completely (Figures 4d & 5d) , similar to Y27632 (Figures 4b & 5b These results again reveal the separate roles performed by the distinct yet closely homologous isoforms, myosins IIA and IIB (Wylie and Chantler, 2001 ). They show, for the first time, that myosin IIA but not myosin IIB drives growth cone collapse and neurite retraction. Our data, taken together with the work of others (Amano et al., 1998; Hirose et al., 1998; Katoh et al., 1998a) , place the regulation of myosin IIA downstream of Rho and Rho-kinase activity, and imply that a different pathway regulates the reciprocal functions of myosin IIB. It is likely that this latter control pathway is regulated upstream by Rac, the overexpression of which is known to induce neurite outgrowth (Albertinazzi et al., 1998) and which has been shown to regulate the phosphorylation state of the myosin heavy-chain (van Leeuwen et al., 1999) . We infer that the target for heavy chain phosphorylation is myosin IIB, the isoform that has previously been shown (Wylie et al., 1998; Bridgman et al., 2001) to be required for neurite outgrowth.
The above results allow us to construct an overall scheme (Figure 7) for the separate regulation of myosin IIA and myosin IIB functions, one which also incorporates results from several other laboratories (Ridley, 1996; Sanders et al., 1999; van Leeuwen et al., 1999; Bishop and Hall, 2000) . Myosin IIB activity, responding to external agonists, such as bradykinin or NGF, is necessary for neurite outgrowth (Wylie et al., 1998; Bridgman et al., 2001 ) and cell spreading (Diefenbach et al., 2002) . Myosin IIA activity, responding to a variety of external agonists including LPA and thrombin, is required for neurite retraction (this paper) and focal contact formation (Wei and Adelstein, 2000; Wylie and Chantler, 2001) and is likely to be the isoform involved in stress fibre formation (Chrzanowska-Wodnicka and Burridge, 1996) . Communications between pathways have been found which hint at reciprocal upstream control of myosin II isoform activity. These include mutual antagonistic effects of Rho relative to both Rac and Cdc42 (Hirose et al., 1998; Rottner et al., 1999; Sander et al., 1999; Sanders et al., 1999; Bishop and Hall, 2000; Yuan et al., 2003) , reciprocity of activation of neurite outgrowth and inhibition of neurite retraction or cell rounding by cAMP (Gunning et al., 1981; Tigyi et al., 1996b; Hirose et al., 1998) or PAK (Sanders et al., 1999; van Leeuwen et al., 1999) . The two pathways are likely to respond differently to extracellular cues during axonal pathfinding.
The integrated mechanism by which both myosin IIA and myosin IIB contribute to neurite elongation will be discussed elsewhere. However, it is worth noting that the differential localisation of myosin IIB and myosin IIA (Rochlin et al., 1995; Kolega, 1998) , together with the distinct spatial organisation of actin cytoarchitecture with the growth cone (Bridgman and Dailey, 1989; Lewis and Bridgman, 1992) , are critical to their actions. Note that attenuation of neurite outgrowth occurred subsequent to application of the myosin IIB oligonucleotides, and this followed a familiar time-course (see Figure 2 ) even in the continued presence of Y27632. Mean neurite lengths and SEMs are plotted for at least 100
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Figure 7
Scheme to illustrate the separate functions and regulation of conventional non-sarcomeric myosin IIA and myosin IIB. We propose separate pathways to regulate the distinctive functions of non-sarcomeric, conventional myosin isoforms, in particular with regard to the dynamic process of neurite extension. We have shown (this paper) that myosin IIA is the motor involved in neurite retraction, a process that can be triggered by a number of effectors including LPA (Tigyi and Miledi, 1992; Jalink et al., 1993; Jalink et al., 1994; Tigyi et al., 1996a) and thrombin (Jalink and Moolenaar, 1992; Suidan et al., 1992; Jalink et al., 1994) . A direct pathway relating cause and effect is shown (LHS) and involves Rho activation, which, in turn, activates Rho-kinase (Matsui et al., 1996; Ridley, 1996; Bishop and Hall, 2000) . When the myosin binding subunit (MBS) of myosin light chain phosphatase (MLCP) is phosphorylated by activated Rho-kinase (Kimura et al., 1996; Ridley, 1996) , dephosphorylation of the regulatory light chain (RLC) of myosin is inhibited, allowing myosin IIA to maintain a level of activity determined by the level of phosphorylation at Ser19 (Bresnick, 1999) . The activity of Rho-kinase is inhibited by Y27632 (Uehata et al., 1997; Davies et al., 2000) , leading to activation of MLCP, dephosphorylation of myosin IIA and a decline in cross-bridge cycling, preventing retraction.
Interestingly, in vitro studies have demonstrated that the heavy chain of myosin IIA can act as a substrate for protein kinase C (Murakami et al., 1995) and metastasis-associated protein (Mts 1) (Murakami et al, 2000) so dual, or even triple, regulation at the level of the myosin molecule may also be possible. Myosin IIA is also known to be involved in focal contact and stress fibre formation (Chrzanowska-Wodnicka and Burridge, 1996; Wei and Adelstein, 2000; Wylie and Chantler, 2001) , processes that can be also be inhibited by Y27632 (Uehata et al., 1997) . It is likely that there are other intermediates in the pathway shown as indicated by a requirement for two different tyrosine kinases (Aoki et al., 1999) .
We have shown previously that myosin IIB is involved in neurite outgrowth (Wylie et al., 1998) , a process that can be initiated in many neuronal cells by NGF (Gundersen, 1985) shown to correlate with cell spreading (van Leeuwen et al., 1999 (Murakami et al., 1998) . PAK-kinase may also be involved (Sanders et al., 1999; van Leeuwen et al., 1999) and has been demonstrated to phosphorylate the RLC (Chew et al., 1998) in vitro. Once again, the results suggest that some form of dual regulation at the level of the myosin molecule may also be involved.
Putative cross-talk between the pathways has not been included in the interest of clarity, but may involve reciprocal actions of cAMP (Hirose et al., 1998) , PAK (van Leeuwen et al., 1999) and further actions of the small GTPase protein family (Ridley, 1996; Sander et al., 1999; Bishop and Hall, 2000; Yuan et al., 2003) . 
BQ3
MHCIIb 5′-tgattccagaattggatctgc-3′ Antisense, 5′-coding Rat U15766 BQ3R * 5′-ggctacgatgacagctatttt-3′ BQ3 scrambled * * Shown are the oligonucleotide code name, myosin isoform, oligonucleotide sequence, direction and location of the sequence, the species from which the sequence was derived and the database accession number. Asterisks signify that the scrambled antisense control does not correspond to any known sequence in the databanks. 
